XML 150 R126.htm IDEA: XBRL DOCUMENT v3.24.0.1
RS - Summary of equity-settled 2022 Restricted Stock Unit Plan (Details)
12 Months Ended
Jun. 01, 2022
shares
Dec. 31, 2023
EUR (€)
shares
numberOfPeriods
€ / shares
Dec. 31, 2022
EUR (€)
€ / shares
Dec. 31, 2021
EUR (€)
Apr. 18, 2023
€ / shares
Oct. 18, 2022
€ / shares
Jun. 15, 2022
€ / shares
Restricted Stock Unit Plans [Line Items]              
Exercise price of outstanding share options (in EUR per share)   € 34.00 € 13.21        
Percentage of shares designated   40.00%          
Percentage of beneficiaries leaving company   40          
MorphoSys US – June 2022 Restricted Stock Unit Plan              
Restricted Stock Unit Plans [Line Items]              
Performance criteria 100.00%            
Percentage of shares vested 33.00%            
Performance Term of Program in Years   3 years          
Number of performance periods | numberOfPeriods   3          
Length for each performance period term   1 year          
Exercise price of outstanding share options (in EUR per share)   € 34.00     € 18.96   € 18.46
Additions (in shares) | shares 408,956 0          
Expense from equity-settled share-based payment transactions | €   € 2,549,992 € 444,718 € 0      
MorphoSys US – June 2022 Restricted Stock Unit Plan | Top of range              
Restricted Stock Unit Plans [Line Items]              
Performance criteria 175.00%            
MorphoSys US – June 2022 Restricted Stock Unit Plan | Bottom of range              
Restricted Stock Unit Plans [Line Items]              
Performance criteria 0.00%            
MorphoSys US - October 2022 Restricted Stock Unit Plan              
Restricted Stock Unit Plans [Line Items]              
Performance Term of Program in Years   3 years          
Number of performance periods | numberOfPeriods   3          
Exercise price of outstanding share options (in EUR per share)   € 34.00     € 18.96 € 22.22  
Additions (in shares) | shares   0          
Percentage of beneficiaries leaving company   0.20